Barclays Records £110 Million Impairment, Sees 3.9% Stock Drop Over Tricolor Lawsuit
Barclays faces a new lawsuit from Tricolor noteholders alleging underwriting failures, triggering a £110 million impairment and a 3.9% share decline with potential for further legal costs. The bank’s analyst team initiated coverage of U.S. large-cap biopharma with a Neutral view and Overweight ratings on Eli Lilly and Bristol-Myers Squibb.
1. Lawsuit Filed by Tricolor Noteholders
Investors holding over $230 million of Tricolor notes have sued Barclays, JPMorgan and Fifth Third in Manhattan federal court, alleging the banks ignored multiple audit warnings when underwriting asset-backed securities. The complaint claims Barclays earned fees while securitizing loans that auditors flagged for misreported payments and misstated delinquencies, prompting a £110 million impairment and a 3.9% drop in shares.
2. Pharma Coverage Initiation
Barclays analyst Emily Field launched coverage of the U.S. large-cap biopharma sector with a Neutral view, citing pharma’s ability to leverage AI for drug discovery. The team rated Eli Lilly and Bristol-Myers Squibb Overweight, highlighting Lilly’s Q4 revenue beat driven by Zepbound and Mounjaro and the sector’s defensive appeal against AI-driven disruptions.